US-based Watchmaker Genomics has announced a multi-year, co-exclusive agreement with compatriot firm Exact Sciences Corporation to develop and commercialize the breakthrough DNA methylation analysis technology known as TET-assisted pyridine borane sequencing (TAPS). Watchmaker will utilize its expertise in engineering DNA-modifying enzymes to enhance the TAPS chemistry, enabling advanced applications such as cancer screening and minimal residual disease (MRD) testing.
Enhancing TAPS Chemistry and Expanding Applications
Under the licensing agreement, Watchmaker Genomics will have the opportunity to develop and commercialize the TAPS technology under its own brand, further improving its capabilities. This collaboration aims to leverage the strengths of both companies to advance the field of DNA methylation analysis and bring innovative solutions to market.
Strategic Supply Agreement to Enhance Performance and Reduce Costs
In addition to the development and licensing agreement, Watchmaker Genomics and Exact Sciences have entered into a long-term strategic supply agreement. Under this agreement, Watchmaker will provide Exact Sciences with access to its portfolio of best-in-class sequencing reagents and precision enzymes. These products are expected to enhance the performance of Exact Sciences’ tests and significantly reduce associated costs, offering a competitive edge in the market.-Fineline Info & Tech
